-+ 0.00%
-+ 0.00%
-+ 0.00%

Racura Oncology's seamless phase 2b/3 Emili trial for recurrent or refractory acute myeloid leukemia received initial center approval.

Zhitongcaijing·11/18/2026 12:41:43
Listen to the news
Racura Oncology's seamless phase 2b/3 Emili trial for recurrent or refractory acute myeloid leukemia received initial center approval.